These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 1831632)

  • 1. Methodology in anti-emetic trials.
    Gralla RJ; Clark RA; Kris MG; Tyson LB
    Eur J Cancer; 1991; 27 Suppl 1():S5-8; discussion S22. PubMed ID: 1831632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodology and assessment in clinical anti-emetic research: a meta-analysis of outcome parameters.
    Morrow GR
    Br J Cancer Suppl; 1992 Dec; 19():S38-41. PubMed ID: 1467200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problems in antiemetic trial design and interpretation.
    Krasnow SH
    Oncology (Williston Park); 1989 Aug; 3(8 Suppl):5-10. PubMed ID: 2701576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-emetic therapy in cancer chemotherapy: current status.
    Herrstedt J; Dombernowsky P
    Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
    Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
    J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
    Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy of malignant tumors, vomiting and nausea--what to do?].
    Ell C; König HJ
    Fortschr Med; 1984 Oct; 102(37):913-5. PubMed ID: 6500448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The symptomatic control of cytostatic drug-induced emesis. A recent history and review.
    Joss RA; Brand BC; Buser KS; Cerny T
    Eur J Cancer; 1990; 26 Suppl 1():S2-8. PubMed ID: 2169781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT3 receptor antagonists for prevention of late acute-onset emesis.
    Constenla M
    Ann Pharmacother; 2004 Oct; 38(10):1683-91. PubMed ID: 15316106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
    Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
    Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy.
    Stuart-Harris RC; Mooney CA; Smith IE
    Clin Oncol; 1983 Jun; 9(2):143-6. PubMed ID: 6309451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
    Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
    Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy-induced nausea and vomiting: from experimentation to experience].
    Marty M
    Bull Cancer; 1996 Dec; 83(12):1014-8. PubMed ID: 9116365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of acupressure studies for chemotherapy-induced nausea and vomiting control.
    Lee J; Dodd M; Dibble S; Abrams D
    J Pain Symptom Manage; 2008 Nov; 36(5):529-44. PubMed ID: 18440769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
    Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
    Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support.
    Ballen KK; Hesketh AM; Heyes C; Becker PS; Emmons RV; Fogarty K; LaPointe J; Liu Q; Hsieh CC; Hesketh PJ
    Bone Marrow Transplant; 2001 Dec; 28(11):1061-6. PubMed ID: 11781617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative trial of granisetron versus granisetron plus methylprednisolone for the prevention of nausea and vomiting induced by cancer chemotherapy].
    Hirota T; Shimizu H; Fujimoto T; Koike A; Kojima T; Noguchi M; Yabushita H; Kato R; Daimaru O; Noda A
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):91-6. PubMed ID: 8291920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.